Update on Metastatic Uveal Melanoma

Progress and Challenges

Francesco Spagnolo, Virginia Picasso, Laura Spano, Enrica Tanda, Clary Venzano, Paola Queirolo

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Uveal melanoma is a rare and biologically distinct type of melanoma arising from melanocytes of the uveal tract; it is associated with a poor prognosis due to the lack of effective systemic treatments. Recent advances in the pathogenesis of uveal melanoma offer an unprecedented opportunity for investigation of new compounds. The purpose of this paper was to analyse the existing evidence about the molecular pathology and immunobiology of advanced uveal melanoma and their implications for systemic targeted therapies and immunotherapy, as well as to discuss future treatment strategies based on data provided by clinical and translational research studies.

Original languageEnglish
Pages (from-to)1-12
Number of pages12
JournalBioDrugs
DOIs
Publication statusAccepted/In press - Mar 21 2016

Fingerprint

Translational Medical Research
Molecular Pathology
Melanocytes
Immunotherapy
Melanoma
Therapeutics
Uveal melanoma

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Pharmacology
  • Biotechnology

Cite this

Spagnolo, F., Picasso, V., Spano, L., Tanda, E., Venzano, C., & Queirolo, P. (Accepted/In press). Update on Metastatic Uveal Melanoma: Progress and Challenges. BioDrugs, 1-12. https://doi.org/10.1007/s40259-016-0167-4

Update on Metastatic Uveal Melanoma : Progress and Challenges. / Spagnolo, Francesco; Picasso, Virginia; Spano, Laura; Tanda, Enrica; Venzano, Clary; Queirolo, Paola.

In: BioDrugs, 21.03.2016, p. 1-12.

Research output: Contribution to journalArticle

Spagnolo, Francesco ; Picasso, Virginia ; Spano, Laura ; Tanda, Enrica ; Venzano, Clary ; Queirolo, Paola. / Update on Metastatic Uveal Melanoma : Progress and Challenges. In: BioDrugs. 2016 ; pp. 1-12.
@article{679367a740c149238de431ab21d4af32,
title = "Update on Metastatic Uveal Melanoma: Progress and Challenges",
abstract = "Uveal melanoma is a rare and biologically distinct type of melanoma arising from melanocytes of the uveal tract; it is associated with a poor prognosis due to the lack of effective systemic treatments. Recent advances in the pathogenesis of uveal melanoma offer an unprecedented opportunity for investigation of new compounds. The purpose of this paper was to analyse the existing evidence about the molecular pathology and immunobiology of advanced uveal melanoma and their implications for systemic targeted therapies and immunotherapy, as well as to discuss future treatment strategies based on data provided by clinical and translational research studies.",
author = "Francesco Spagnolo and Virginia Picasso and Laura Spano and Enrica Tanda and Clary Venzano and Paola Queirolo",
year = "2016",
month = "3",
day = "21",
doi = "10.1007/s40259-016-0167-4",
language = "English",
pages = "1--12",
journal = "Clinical Immunotherapeutics",
issn = "1173-8804",
publisher = "Adis International Ltd",

}

TY - JOUR

T1 - Update on Metastatic Uveal Melanoma

T2 - Progress and Challenges

AU - Spagnolo, Francesco

AU - Picasso, Virginia

AU - Spano, Laura

AU - Tanda, Enrica

AU - Venzano, Clary

AU - Queirolo, Paola

PY - 2016/3/21

Y1 - 2016/3/21

N2 - Uveal melanoma is a rare and biologically distinct type of melanoma arising from melanocytes of the uveal tract; it is associated with a poor prognosis due to the lack of effective systemic treatments. Recent advances in the pathogenesis of uveal melanoma offer an unprecedented opportunity for investigation of new compounds. The purpose of this paper was to analyse the existing evidence about the molecular pathology and immunobiology of advanced uveal melanoma and their implications for systemic targeted therapies and immunotherapy, as well as to discuss future treatment strategies based on data provided by clinical and translational research studies.

AB - Uveal melanoma is a rare and biologically distinct type of melanoma arising from melanocytes of the uveal tract; it is associated with a poor prognosis due to the lack of effective systemic treatments. Recent advances in the pathogenesis of uveal melanoma offer an unprecedented opportunity for investigation of new compounds. The purpose of this paper was to analyse the existing evidence about the molecular pathology and immunobiology of advanced uveal melanoma and their implications for systemic targeted therapies and immunotherapy, as well as to discuss future treatment strategies based on data provided by clinical and translational research studies.

UR - http://www.scopus.com/inward/record.url?scp=84961793487&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84961793487&partnerID=8YFLogxK

U2 - 10.1007/s40259-016-0167-4

DO - 10.1007/s40259-016-0167-4

M3 - Article

SP - 1

EP - 12

JO - Clinical Immunotherapeutics

JF - Clinical Immunotherapeutics

SN - 1173-8804

ER -